1
|
Cacciotto C, Dore GM, Cubeddu T, Burrai GP, Anfossi AG, Antuofermo E, Varoni MV, Demontis MP, Zobba R, Pittau M, Müller M, Alberti A. Ovine papillomavirus type 3 virus-like particle-based tools for diagnosis and detection of infection. Vaccine 2024:S0264-410X(24)00660-1. [PMID: 38839520 DOI: 10.1016/j.vaccine.2024.06.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2024] [Revised: 05/03/2024] [Accepted: 06/01/2024] [Indexed: 06/07/2024]
Abstract
The design of prophylactic and diagnostic tools specific to animal papillomaviruses is hampered by the difficulties of viral in vitro manipulation and by the scarce availability of dedicated biotechnological tools. This paper reports the production of Ovine Papillomavirus 3 (OaPV3)-based virus-like particles (OaPV3-VLPs) in the baculovirus system and their use to investigate host humoral immune response through the establishment of an indirect ELISA test., Polyclonal sera and monoclonal antibodies were generated against OaPV3-VLPs, and their isotype and reactivity were determined. Additionally, antibodies allowed OaPV3 detection in ovine squamous cell carcinoma (SCC) samples by immunohistochemistry. Results encourage the standardization of OaPV3-specific prophylactic and serological diagnostic tools, and open new perspectives for the study of host-viral interaction and SCC development.
Collapse
Affiliation(s)
- Carla Cacciotto
- Università degli Studi di Sassari, Dipartimento di Medicina Veterinaria, Sassari, Italy; Mediterranean Center for Disease Control, Sassari, Italy
| | - Gian Mario Dore
- Università degli Studi di Sassari, Dipartimento di Medicina Veterinaria, Sassari, Italy
| | - Tiziana Cubeddu
- Università degli Studi di Sassari, Dipartimento di Medicina Veterinaria, Sassari, Italy; Mediterranean Center for Disease Control, Sassari, Italy
| | - Giovanni Pietro Burrai
- Università degli Studi di Sassari, Dipartimento di Medicina Veterinaria, Sassari, Italy; Mediterranean Center for Disease Control, Sassari, Italy
| | | | - Elisabetta Antuofermo
- Università degli Studi di Sassari, Dipartimento di Medicina Veterinaria, Sassari, Italy; Mediterranean Center for Disease Control, Sassari, Italy
| | - Maria Vittoria Varoni
- Università degli Studi di Sassari, Dipartimento di Medicina Veterinaria, Sassari, Italy
| | - Maria Piera Demontis
- Università degli Studi di Sassari, Dipartimento di Medicina Veterinaria, Sassari, Italy
| | - Rosanna Zobba
- Università degli Studi di Sassari, Dipartimento di Medicina Veterinaria, Sassari, Italy
| | - Marco Pittau
- Università degli Studi di Sassari, Dipartimento di Medicina Veterinaria, Sassari, Italy; Mediterranean Center for Disease Control, Sassari, Italy
| | | | - Alberto Alberti
- Università degli Studi di Sassari, Dipartimento di Medicina Veterinaria, Sassari, Italy; Mediterranean Center for Disease Control, Sassari, Italy.
| |
Collapse
|
2
|
Vrablikova A, Brezani V, Psikal I, Fraiberk M, Sebela M, Fojtikova M, Kulich P, Hezova R, Masek J. Development of modern immunization agent against bovine papillomavirus type 1 infection based on BPV1 L1 recombinant protein. Front Vet Sci 2023; 10:1116661. [PMID: 37056230 PMCID: PMC10086343 DOI: 10.3389/fvets.2023.1116661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Accepted: 02/27/2023] [Indexed: 03/30/2023] Open
Abstract
Bovine papillomavirus type 1 L1 protein was produced in a baculovirus expression system and purified as virus-like particles (VLPs) by affinity chromatography using lectins. The morphological integrity of VLPs was confirmed by electron microscopy. Differences between the two detected variants were deciphered by mass spectrometry of peptides (MALDI-TOF). Mice were immunized with purified VLPs in doses of 10, 25, or 50 μg in combination with 1% saponin and 15% alhydrogel per dose as adjuvants. Analysis of the humoral immune response revealed increased levels of specific antibodies detected 3 weeks after the first immunization in all groups of animals. This was further significantly increased by the booster applied 3 weeks after the first dose, with the best immune response in a group of mice immunized by the largest dose of antigen. BPV1 L1 VLPs purified by affinity chromatography using lectins could be used for prophylactic immunization in veterinary medicine.
Collapse
Affiliation(s)
- Alena Vrablikova
- Department of Pharmacology and Toxicology, Veterinary Research Institute, Brno, Czechia
- *Correspondence: Alena Vrablikova
| | - Veronika Brezani
- Department of Pharmacology and Toxicology, Veterinary Research Institute, Brno, Czechia
| | - Ivan Psikal
- Department of Pharmacology and Toxicology, Veterinary Research Institute, Brno, Czechia
- Dyntec spol s. r.o., Terezin, Czechia
| | - Martin Fraiberk
- Dyntec spol s. r.o., Terezin, Czechia
- Faculty of Science, Charles University, Prague, Czechia
| | - Marek Sebela
- Department of Biochemistry, Faculty of Science, Palacký University, Olomouc, Czechia
| | - Martina Fojtikova
- Department of Pharmacology and Toxicology, Veterinary Research Institute, Brno, Czechia
| | - Pavel Kulich
- Department of Pharmacology and Toxicology, Veterinary Research Institute, Brno, Czechia
| | - Renata Hezova
- Department of Pharmacology and Toxicology, Veterinary Research Institute, Brno, Czechia
| | - Josef Masek
- Department of Pharmacology and Toxicology, Veterinary Research Institute, Brno, Czechia
| |
Collapse
|
3
|
Hainisch EK, Jindra C, Kirnbauer R, Brandt S. Papillomavirus-like Particles in Equine Medicine. Viruses 2023; 15:v15020345. [PMID: 36851559 PMCID: PMC9966523 DOI: 10.3390/v15020345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2022] [Revised: 01/19/2023] [Accepted: 01/21/2023] [Indexed: 01/27/2023] Open
Abstract
Papillomaviruses (PVs) are a family of small DNA tumor viruses that can induce benign lesions or cancer in vertebrates. The observation that animal PV capsid-proteins spontaneously self-assemble to empty, highly immunogenic virus-like particles (VLPs) has led to the establishment of vaccines that efficiently protect humans from specific PV infections and associated diseases. We provide an overview of PV-induced tumors in horses and other equids, discuss possible routes of PV transmission in equid species, and present recent developments aiming at introducing the PV VLP-based vaccine technology into equine medicine.
Collapse
Affiliation(s)
- Edmund K. Hainisch
- Research Group Oncology (RGO), Clinical Unit of Equine Surgery, Department for Companion Animals and Horses, Veterinary University, 1210 Vienna, Austria
| | - Christoph Jindra
- Research Group Oncology (RGO), Clinical Unit of Equine Surgery, Department for Companion Animals and Horses, Veterinary University, 1210 Vienna, Austria
- Division of Molecular Oncology and Haematology, Karl Landsteiner University of Health Sciences, 3500 Krems an der Donau, Austria
| | - Reinhard Kirnbauer
- Laboratory of Viral Oncology (LVO), Department of Dermatology, Medical University, 1090 Vienna, Austria
| | - Sabine Brandt
- Research Group Oncology (RGO), Clinical Unit of Equine Surgery, Department for Companion Animals and Horses, Veterinary University, 1210 Vienna, Austria
- Correspondence:
| |
Collapse
|
4
|
A broadly protective vaccine against cutaneous human papillomaviruses. NPJ Vaccines 2022; 7:116. [PMID: 36216845 PMCID: PMC9550855 DOI: 10.1038/s41541-022-00539-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2022] [Accepted: 09/08/2022] [Indexed: 11/19/2022] Open
Abstract
Skin colonization by human papillomavirus (HPV) is typically related to inconspicuous cutaneous infections without major disease or complications in immunocompetent individuals. However, in immunosuppressed patients, especially organ transplanted recipients, cutaneous HPV infections may cause massive, highly spreading and recurrent skin lesions upon synergism with UV-exposure. Current HPV prophylactic vaccines are not effective against cutaneous HPV types (cHPV). By applying a modular polytope-based approach, in this work, we explored different vaccine candidates based on selected, tandemly arranged cHPV-L2 epitopes fused to thioredoxin (Trx) as a scaffold protein. Upon conversion to heptameric nanoparticles with the use of a genetically fused oligomerization domain, our candidate Trx-L2 vaccines induce broadly neutralizing immune responses against 19 cHPV in guinea pigs. Similar findings were obtained in mice, where protection against virus challenge was also achieved via passive transfer of immune sera. Remarkably, immunization with the candidate cHPV vaccines also induced immune responses against several mucosal low- and high-risk HPV types, including HPV16 and 18. Based on cumulative immunogenicity data but also on ease and yield of production, we identified a lead vaccine candidate bearing 12 different cHPV-L2 epitopes that holds great promise as a scalable and GMP production-compatible lead molecule for the prevention of post-transplantation skin lesions caused by cHPV infection.
Collapse
|
5
|
Evidence from a Series of 104 Equine Sarcoids Suggests That Most Sarcoids in New Zealand Are Caused by Bovine Papillomavirus Type 2, although Both BPV1 and BPV2 DNA Are Detectable in around 10% of Sarcoids. Animals (Basel) 2021; 11:ani11113093. [PMID: 34827825 PMCID: PMC8614326 DOI: 10.3390/ani11113093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2021] [Revised: 10/23/2021] [Accepted: 10/26/2021] [Indexed: 11/23/2022] Open
Abstract
Simple Summary Equine sarcoids are common cancers of horses that are caused by bovine papillomaviruses (BPVs). Previous studies have suggested that most sarcoids are caused by either BPV1 or BPV2, with the proportion caused by each BPV type dependent on the country in which the horse lived. Additionally, some studies also suggest that other papillomavirus (PV) types could cause equine sarcoids. The study was comprised of 104 sarcoids from New Zealand horses and used both specific and consensus PCR primer sets. Overall, PV DNA was amplified from 90% of the sarcoids. Of the ones that contained BPV DNA, 88% contained only BPV2 DNA, 10% BPV1 and BPV2 DNA, and 2% only BPV1 DNA. Only the primers specific for BPV1 or specific for BPV2 amplified DNA and no other PV types were detected. There was little variability in the rates of detection between different regions of New Zealand and rates were consistent when two distinct time periods were compared. These results suggest that sarcoids from New Zealand horses are consistently most often caused by BPV2 and thus if vaccination is used to prevent these cancers, it will be important to use a vaccine that provides good protection against this BPV type. Abstract Equine sarcoids are common mesenchymal neoplasms of horses that are caused by cross-species infection by deltapapillomaviruses. While bovine papillomavirus (BPV) 1 and 2 are the most common causes, there are differences between countries regarding which of these BPV types cause the majority of sarcoids. Additionally, no causative PV can be detected in a subset of sarcoids, suggesting that other PV types could be rarer causes of these neoplasms. In the present study, consensus PCR primers and PCR primers specific for the five deltapapillomavirus types currently known to cause mesenchymal neoplasia (BPV1, BPV2, BPV13, BPV14, and Ovis aries PV2 DNA) were used to investigate the presence of PV DNA in 104 sarcoids from three defined regions in New Zealand and from two distinct time periods separated by 15 years. PV DNA was detected in 94 (90.4%) sarcoids. Of the sarcoids containing PV DNA, 83 (88.3%) contained only BPV2 DNA, 9 (9.6%) BPV1 and BPV2 DNA, and 2 (2.1%) only BPV1 DNA. No other PV types were detected. The predominance of BPV2 is consistent with studies of sarcoids from North America but dissimilar to studies of sarcoids from Europe and Australia. Detection rates of BPV1 and BPV2 were similar in sarcoids from different regions of New Zealand and in sarcoids from different time periods. These results suggest that most equine sarcoids in New Zealand are caused by BPV2 and thus if vaccines are developed to prevent sarcoids, vaccines that provide good protection against BPV2 will be required in this country.
Collapse
|
6
|
Jindra C, Kamjunke AK, Jones S, Brandt S. Screening for bovine papillomavirus type 13 (BPV13) in a European population of sarcoid-bearing equids. Equine Vet J 2021; 54:662-669. [PMID: 34459020 PMCID: PMC9292424 DOI: 10.1111/evj.13501] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Revised: 06/24/2021] [Accepted: 08/19/2021] [Indexed: 01/03/2023]
Abstract
BACKGROUND Bovine papillomavirus types 1 and 2 (BPV1 and BPV2) are accepted aetiological agents of equine sarcoids. Recently, genetically similar BPV13 has been identified from equine sarcoids in Brazil. OBJECTIVES To determine whether BPV13 DNA can be also found in sarcoid-affected horses in Austria, and donkeys in Northern Italy and the UK, and should hence be considered in the context of vaccine-mediated sarcoid prevention. STUDY DESIGN Cross sectional study. METHODS A total of 194 archival, equine and asinine DNA isolates derived from confirmedly delta-BPV-positive tumours were subjected to quality control by photometric analysis and equine beta-actin PCR. Isolates with DNA concentrations >0.9 ng/µl and confirmed PCR-compatibility (n = 135) were subsequently screened for the presence of BPV13 DNA using BPV13-specific PCR primers for amplification of a 771 bp region comprising the BPV13 E5 gene. RESULTS BPV13 E5 PCR scored negative for all 135 samples. Included positive, negative and no-template controls yielded anticipated results, thus confirming reliability of obtained data. MAIN LIMITATIONS Moderate number of tested tumour DNA extracts (n = 135; equivalent to 127 tumour-affected equids). CONCLUSIONS Despite its moderate size, the sample was considered representative enough to suggest a low occurrence of BPV13 in Austria, as it randomly comprised equine patients of different breed, age, gender, and European provenience. BPV13 was not associated with tested sarcoids in rescued donkeys originating from several other European countries. Large-scale BPV13 screenings are necessary to allow for a more precise estimation of the prevalence and distribution of BPV13 infections in European equids suffering from sarcoid disease.
Collapse
Affiliation(s)
- Christoph Jindra
- Research Group Oncology (RGO), Clinical Unit of Equine Surgery, University Clinic for Horses, University of Veterinary Medicine, Vienna, Austria
| | - Ann-Kristin Kamjunke
- Research Group Oncology (RGO), Clinical Unit of Equine Surgery, University Clinic for Horses, University of Veterinary Medicine, Vienna, Austria
| | - Sarah Jones
- School of Veterinary Medicine, University of Glasgow, Scotland, UK
| | - Sabine Brandt
- Research Group Oncology (RGO), Clinical Unit of Equine Surgery, University Clinic for Horses, University of Veterinary Medicine, Vienna, Austria
| |
Collapse
|
7
|
Ogłuszka M, Starzyński RR, Pierzchała M, Otrocka-Domagała I, Raś A. Equine Sarcoids-Causes, Molecular Changes, and Clinicopathologic Features: A Review. Vet Pathol 2021; 58:472-482. [PMID: 33461443 DOI: 10.1177/0300985820985114] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Equine sarcoid is the most common skin tumor of horses. Clinically, it occurs as a locally invasive, fibroblastic, wart-like lesion of equine skin, which has 6 clinical classes: occult, verrucose, nodular, fibroblastic, mixed, and malignant. Sarcoids may be single but multiple lesions are more frequent. The typical histological feature is increased density of dermal fibroblasts which form interlacing bundles and whorls within the dermis. Lesions are mostly persistent, resist therapy, and tend to recur following treatment. In general, sarcoids are not fatal but their location, size, and progression to the more aggressive form may lead to the withdrawal of a horse from use and serious infringement of their welfare leading to the loss of valuable animals. Bovine papillomavirus (BPV) type 1 and less commonly type 2 contribute to the development of equine sarcoid. The viral genome and proteins are detected in a high percentage of cases. Furthermore, viral oncoprotein activity leads to changes in the fibroblastic tissue similar to changes seen in other types of tumors. Equine sarcoids are characterized by a loss of tumor suppressor activity and changes allowing abnormal formation of the affected tissue, as well as y immune defense abnormalities that weaken the host's immune response. This impaired immune response to BPV infection appears to be crucial for the development of lesions that do not spontaneously regress, as occurs in BPV-infected cows.
Collapse
Affiliation(s)
- Magdalena Ogłuszka
- Institute of Genetics and Animal Biotechnology of the 49559Polish Academy of Sciences, Jastrzębiec, Poland
| | - Rafał Radosław Starzyński
- Institute of Genetics and Animal Biotechnology of the 49559Polish Academy of Sciences, Jastrzębiec, Poland
| | - Mariusz Pierzchała
- Institute of Genetics and Animal Biotechnology of the 49559Polish Academy of Sciences, Jastrzębiec, Poland
| | | | - Andrzej Raś
- 49674University of Warmia and Mazury, Olsztyn, Poland
| |
Collapse
|
8
|
Watanabe S, Shibahara T, Andoh K, Hatama S, Mase M. Production of immunogenic recombinant L1 protein of bovine papillomavirus type 9 causing teat papillomatosis. Arch Virol 2020; 165:1441-1444. [PMID: 32239294 DOI: 10.1007/s00705-020-04612-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2019] [Accepted: 03/06/2020] [Indexed: 11/25/2022]
Abstract
Bovine papillomavirus type 9 (BPV9) is a causative agent of severe teat papillomatosis. Considering the lack of efficient BPV culture methods, recombinant proteins such as virus-like particles developed through genetic engineering may serve as a useful tool for developing effective vaccines against BPV infection. In this study, we successfully produced immunogenic particles composed of recombinant L1 protein of BPV9 (rBPV9-L1), using a baculovirus expression system. rBPV9-L1-immunized mice produced BPV9-specific IgG, which did not cross-react with BPV type 6, which is another causative agent of teat papillomatosis. Hence, immunogenic rBPV9-L1 is potentially applicable as a vaccine candidate for teat papillomatosis.
Collapse
Affiliation(s)
- Satoko Watanabe
- National Institute of Animal Health, NARO, 3-1-5 Kannondai, Tsukuba, Ibaraki, 305-0856, Japan.
| | - Tomoyuki Shibahara
- National Institute of Animal Health, NARO, 3-1-5 Kannondai, Tsukuba, Ibaraki, 305-0856, Japan
- Department of Veterinary Science, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, 1-58 Rinku-oraikita, Izumisano, Osaka, 598-8531, Japan
| | - Kiyohiko Andoh
- National Institute of Animal Health, NARO, 3-1-5 Kannondai, Tsukuba, Ibaraki, 305-0856, Japan
| | - Shinichi Hatama
- National Institute of Animal Health, NARO, 3-1-5 Kannondai, Tsukuba, Ibaraki, 305-0856, Japan
| | - Masaji Mase
- National Institute of Animal Health, NARO, 3-1-5 Kannondai, Tsukuba, Ibaraki, 305-0856, Japan
- United Graduate School of Veterinary Sciences, Gifu University, 1-1 Yanagido, Gifu, Gifu, 501-1193, Japan
| |
Collapse
|